Today: 29 April 2026
Browse Category

STO:VOLV.B 5 February 2026

Volvo Car AB stock sinks 22% as Q4 profit slumps and tariffs bite

Volvo Car AB stock sinks 22% as Q4 profit slumps and tariffs bite

Volvo Car AB shares plunged 22% to 23.05 crowns in Stockholm after fourth-quarter adjusted operating profit fell to 1.8 billion crowns, down from 5.6 billion a year earlier. Revenue dropped to 94.4 billion crowns, and gross margin slipped to 15.8%. The company cited tariffs, weak demand, and pricing pressure. Volvo warned of a challenging 2026 and flagged negative cash flow in the first half due to inventory build-up.
5 February 2026
··

Stock Market Today

  • TSX Picks: Aecon Group, Savaria Among Undervalued Stocks with Upside Potential
    April 29, 2026, 9:24 AM EDT. Investors eye undervalued TSX stocks amid volatile fuel prices and steady interest rates. Aecon Group (TSX:ARE), a CA$3.36 billion construction firm, trades 24.8% below estimated fair value, boosted by rising Q1 sales and a strong project pipeline. Savaria Corporation (TSX:SIS), specializing in accessibility solutions with a CA$2.15 billion market cap, is down 32.2% against fair value. Both companies show promising earnings growth projections, potentially rewarding investors as market conditions stabilize. These stocks highlight opportunities found through cash flow-based valuation methods amid an uncertain economic backdrop.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop